![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bharat Biotech Finalizes Enrollment for Phase 3 COVID-19 Vaccine Trial
Bharat Biotech Finalizes Enrollment for Phase 3 COVID-19 Vaccine Trial
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
January 11, 2021
India’s Bharat Biotech has finalized enrollment for a phase 3 trial of its COVID-19 vaccine, Covaxin, which Indian regulators approved Jan. 3 for emergency use.
The study, involving almost 26,000 participants, is the largest phase 3 vaccine trial ever conducted in India, Bharat says. According to ClinicalTrials.gov, the phase 3 study has an expected primary completion date of June 30 and a study completion date of March 1, 2022.
The two-dose vaccine was previously evaluated in approximately 1,000 volunteers in early-stage trials, where it demonstrated positive immunogenicity and safety.
Vaccine experts have questioned India’s emergency approval in the absence of reliable data from the late-stage trial, which only got under way in mid-November.
Upcoming Events
-
21Oct